Cyteir Therapeutics Series A Financing
by David E Shaw
I’m pleased to announce, as a co-founder, that Cyteir Therapeutics has closed a $5.5 mm Series A financing and recruited Donald Corcoran as CEO.
We have worked closely with The Jackson Laboratory on this new venture and are excited about the prospects of the company’s cancer therapy technology. It’s important to note that related science about DNA repair mechanisms was recognized via the Nobel Prize for chemistry recently. Congratulations to the The Jackson Laboratory, the founding team and others for this important milestone.